BACKGROUND The health status of the East Timorese population is very poor and much of the health system was destroyed during the violence of 1999. As in other developing countries, the lack of appropriate and high quality medicines significantly compromises patient care throughout the health system. The aim of this study was to examine the purchase, distribution and supply of pharmaceuticals in...

BACKGROUND Government- and charity-funded medical research and private sector research and development (R&D) are widely held to be complements. The only attempts to measure this complementarity so far have used data from the United States of America and are inevitably increasingly out of date. This study estimates the magnitude of the effect of government and charity biomedical and health resea...

Background: In Tanzania, many people seek malaria treatment from retail drug sellers. The National Malaria Control Program identified the accredited drug dispensing outlet (ADDO) program as a private sector mechanism to supplement the distribution of subsidized artemisinin-based combination therapies (ACTs) from public facilities and increase access to the first-line antimalarial in rural and u...

The Data mining is gradually becoming an integral and essential part of health and pharmaceutical industry. Data mining techniques are being regularly used to assess efficacy of treatment, management of ailments, and also in various stages of drug discovery and process research. Off late, data mining has become a boon in health insurance sector to minimize frauds and abuse. A good number of hea...

The dramatic growth of research and development activities in the pharmaceutical sector in emerging economies raises the question of whether the United States still keeps its dominant role in the global pharmaceutical innovation landscape. This paper focuses on investigating the role of the United States in global pharmaceutical innovation, and differs from previous studies by shifting attentio...

INTRODUCTION Policy-makers worldwide struggle to balance health with industrial policy objectives in the pharmaceutical sector. Tensions arise over pricing and reimbursement in particular. What health plans view as necessary to maintain equitable access to medicines, industry views as inimical to R&D and innovation. Australia has grappled with this issue for years, even incorporating the goal o...

OBJECTIVE To review the pharmaceutical sector in Cyprus in terms of the availability and affordability of medicines and to explore pharmaceutical policy options for the national health system finance reform expected to be introduced in 2016. METHODS We conducted semi-structured interviews in April 2014 with senior representatives from seven key national organizations involved in pharmaceutica...

a 51 hour (3 credit) lecture course entitled pharmaceutical biotechnology is outlined which details the biochemistry and biotechnology of biological drug products. it is designed to equip students undertaking pharmacy program with an understanding of concepts, both academic and applied, directly relevant to working in the biotechnological products sector. in addition to the course, a bank of re...